Short answer
CATALYST PHARMACEUTICALS, INC. (CPRX) filed an 8-K current report with the SEC on March 18, 2026 reporting Item 8.01 (Other Events). Trial delay from March 23 to May 18, 2026 on patent validity for FIRDAPSE® listed in Orange Book.
CATALYST PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Trial delay from March 23 to May 18, 2026 on patent validity for FIRDAPSE® listed in Orange Book
- Patents under dispute expire in 2032, 2034, and 2037, critical for protecting FIRDAPSE® revenue
- Delay prolongs uncertainty over intellectual property rights and market exclusivity for key drug
- Outcome of trial could impact future sales, competitive positioning, and valuation of Catalyst Pharmaceuticals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CATALYST PHARMACEUTICALS, INC. 8-K filings
Get the next CPRX 8-K as it lands
Follow CPRX for push alerts, or ask the research agent what this filing means.